Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Biocryst Pharma Inc 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 USA

www.biocryst.com Employees: 536 P: 919-859-1302 F: 919-859-1314

Description:

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.

Key Statistics

Overview:

Market Capitalization, $K 1,456,145
Enterprise Value, $K 2,178,535
Shares Outstanding, K 207,133
Annual Sales, $ 331,410 K
Annual Net Income, $ -226,540 K
Last Quarter Sales, $ 117,090 K
Last Quarter Net Income, $ -14,030 K
EBIT, $ -40,720 K
EBITDA, $ -49,330 K
60-Month Beta 1.89
% of Insider Shareholders 4.80%
% of Institutional Shareholders 85.88%
Float, K 197,191
% Float 95.20%
Short Volume Ratio 0.59

Growth:

1-Year Return 32.34%
3-Year Return -40.87%
5-Year Return 212.44%
5-Year Revenue Growth 1,504.89%
5-Year Earnings Growth -2.04%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.07 on 11/04/24
Next Earnings Date N/A
Earnings Per Share ttm -0.58
EPS Growth vs. Prev Qtr -16.67%
EPS Growth vs. Prev Year 63.16%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

BCRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -24.06%
Profit Margin % -68.36%
Debt/Equity -1.77
Price/Sales 4.66
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -2.26
Interest Coverage -1.09
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar